Revolution Medicines Inc. (RVMD)
| Bid | 28.88 |
| Market Cap | 7.54B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -600.09M |
| EPS (ttm) | -3.58 |
| PE Ratio (ttm) | -11.32 |
| Forward PE | -8.24 |
| Analyst | Buy |
| Ask | 51.26 |
| Volume | 466,220 |
| Avg. Volume (20D) | 1,845,846.4 |
| Open | 40.40 |
| Previous Close | 40.38 |
| Day's Range | 39.59 - 40.89 |
| 52-Week Range | 29.17 - 62.40 |
| Beta | 1.37 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells...
Analyst Forecast
According to 11 analyst ratings, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 65.27% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call TranscriptRevolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairm...
